Current and emerging therapeutic options for the management of functional dyspepsia

References

• Stanghellini V, Talley N, Chan F, et al. Functional gastroduodenal disorders. Gastroenterology. 2016 May;150(6):1380–1392.
   PubMed Web of Science ®Google Scholar
• Aziz I, Palsson OS, Törnblom H, et al. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. Lancet Gastroenterol Hepatol. 2018 Apr;3(4):252–262.
   PubMed Web of Science ®Google Scholar
• Piessevaux H, De Winter B, Louis E, et al. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol Motil. 2009 Apr;21(4):378–388.
   PubMed Web of Science ®Google Scholar
• Jones MP, Talley NJ, Eslick GD, et al. Community subgroups in dyspepsia and their association with weight loss. Am J Gastroenterol. 2008 Aug;103(8):2051–2056.
   PubMed Web of Science ®Google Scholar
• Tack J, Jones MP, Karamanolis G, et al. Symptom pattern and pathophysiological correlates of weight loss in tertiary-referred functional dyspepsia. Neurogastroenterol Motil. 2010 Jan;22(1):29–35, e4–5.
   Web of Science ®Google Scholar
• Ford AC, Marwaha A, Lim A, et al. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010 Oct;8(10):830–7, 837.e1–2.
   Web of Science ®Google Scholar
• Oustamanolakis P, Tack J. Dyspepsia: organic versus functional. J Clin Gastroenterol. 2012 Mar;46(3):175–190.
   PubMed Web of Science ®Google Scholar
• Tack J, Talley NJ. Functional dyspepsia-symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol. 2013;10:134–141.
   PubMed Web of Science ®Google Scholar
• Van den Houte K, Carbone F, Tack J. Postprandial distress syndrome: stratification and management. Expert Rev Gastroenterol Hepatol. 2019 Aug;3(4):337–343.
   Google Scholar
• Carbone F, Tack J. Gastroduodenal mechanisms underlying functional gastric disorders. Dig Dis. 2014;32(3):222–229.
   PubMed Web of Science ®Google Scholar
• Simrén M, Törnblom H, Palsson OS, et al. Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts. Gut. 2018 Feb;67(2):255–262.
   PubMed Web of Science ®Google Scholar
• Stanghellini V, Tack J. Gastroparesis: separate entity or just a part of dyspepsia? Gut. 2014 Dec;63(12):1972–1978.
   PubMed Web of Science ®Google Scholar
• Janssen P, Harris MS, Jones M, et al. The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol. 2013 Sept;108(9):1382–1391.
   PubMed Web of Science ®Google Scholar
• Vijayvargiya P, Camilleri M, Chedid V, et al. Effects of promotility agents on gastric emptying and symptoms: a systematic review and meta-analysis. Gastroenterology. 2019 May;156(6):1650–1660.
   PubMed Web of Science ®Google Scholar
• Enck P, Azpiroz F, Boeckxstaens G, et al. Functional dyspepsia. Nat Rev Dis Primers. 2017 Nov;3(3):17081.
   PubMedGoogle Scholar
• Camilleri M, Stanghellini V. Current management strategies and emerging treatments for functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013 Mar;10(3):187–194.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017 July;112(7):988–1013.
   PubMed Web of Science ®Google Scholar
• Van Oudenhove L, Vandenberghe J, Geeraerts B, et al. Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation? Gut. 2008 Dec;57(12):1666–1673.
   PubMed Web of Science ®Google Scholar
• Janssen P, Verschueren S, Ly HG, et al. Intragastric pressure during food intake: a physiological and minimally invasive method to assess gastric accommodation. Neurogastroenterol Motil. 2011 Apr;23(4):316–22, e153–4.
   Web of Science ®Google Scholar
• Tack J, Caenepeel P, Piessevaux H, et al. Assessment of meal-induced gastric accommodation by a satiety drinking test in health and in functional dyspepsia. Gut. 2003;52:1271–1277.
   PubMed Web of Science ®Google Scholar
• Sarnelli G, Vos R, Cuomo R, et al. Reproducibility of gastric barostat studies in healthy controls and in dyspeptic patients. Am J Gastroenterol. 2001;96:1047–1053.
   PubMed Web of Science ®Google Scholar
• Kuiken SD, Samsom M, Camilleri M, et al. Development of a test to measure gastric accommodation in humans. Am J Physiol. 1999 Dec;277(6):G1217–21.
   PubMedGoogle Scholar
• Carbone F, Vandenberghe A, Holvoet L, et al. Validation of the leuven postprandial distress scale, a questionnaire for symptom assessment in the functional dyspepsia/postprandial distress syndrome. Aliment Pharmacol Ther. 2016 Nov;44(9):989–1001.
   PubMed Web of Science ®Google Scholar
• Tack J, Carbone F, Holvoet L, et al. The use of pictograms improves symptom evaluation by patients with functional dyspepsia. Aliment Pharmacol Ther. 2014 July–Sept 22;40(5):523–530.
   PubMed Web of Science ®Google Scholar
• Tack J, Masuy I, Van Den Houte K, et al. Drugs under development for the treatment of functional dyspepsia and related disorders. Expert Opin Investig Drugs. 2019;28(10):871–889.
   PubMedGoogle Scholar
• Goelen N, Carbone F, Holvoet L, et al. The waiting room questionnaire: validation of a novel patient reported outcome questionnaire for the diagnosis of functional gastrointestinal disorders. Gastroenterology. 2017 Apr;152(5 Supplement 1):S744–S745.
   Web of Science ®Google Scholar
• Tack J, Pokrotnieks J, Urbonas G, et al. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial. Neurogastroenterol Motil. 2018 June;30(6):e13284.
   PubMed Web of Science ®Google Scholar
• Masuy I, Carbone F 2, Holvoet L 2, et al. The effect of rikkunshito on gastrointestinal symptoms and gastric motor function: the first study in a Belgian functional dyspepsia population. Neurogastroenterol Motil. 2019 Oct 14:e13739.
   Google Scholar
• Tack J, Piessevaux H, Coulie B, et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998 Dec;115(6):1346–1352.
   PubMed Web of Science ®Google Scholar
• Sarnelli G, Caenepeel P, Geypens B, et al. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol. 2003 Apr;98(4):783–788.
   PubMed Web of Science ®Google Scholar
• Tack J, Camilleri M. New developments in the treatment of gastroparesis and functional dyspepsia. Curr Opin Pharmacol. 2018 Dec;43:111–117.
   PubMed Web of Science ®Google Scholar
• Masuy I, Van Oudenhove L, Tack J. Review article: treatment options for functional dyspepsia. Aliment Pharmacol Ther. 2019 May;49(9):1134–1172.
   PubMed Web of Science ®Google Scholar
• Altan E, Masaoka T, Farré R, et al. Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome. Expert Rev Gastroenterol Hepatol. 2012 Sept 6;6(5):533–544. Therap Adv Gastroenterol. 2017 Sep; 10(9): 689–699.
   PubMed Web of Science ®Google Scholar
• Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012 June;61(6):821–828.
   PubMed Web of Science ®Google Scholar
• Matsueda K, Hongo M, Ushijima S, et al. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion. 2011;84(4):261–268.
   PubMed Web of Science ®Google Scholar
• Bor S, Demir M, Ozdemir O, et al. A meta-analysis on the cardiac safety profile of domperidone compared to metoclopramide. United European Gastroenterol J. 2018 Nov;6(9):1331–1346.
   PubMed Web of Science ®Google Scholar
• Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012 Apr;35(7):745–767.
   PubMed Web of Science ®Google Scholar
• Cuena Boy R, Maciá Martínez MA. Extrapyramidal toxicity caused by metoclopramide and clebopride: study of voluntary notifications of adverse effects to the Spanish drug surveillance system. Aten Primaria. 1998 Mar 31;21(5):289–295. Spanish.
   PubMedGoogle Scholar
• Kim K-S, Shin W-H, Park SJ, et al. Effect of clebopride, antidopaminergic gastrointestinal prokinetics, on cardiac repolarization. Int J Toxicol. 2007 Jan–Feb;26(1):25–31.
   PubMed Web of Science ®Google Scholar
• Hallerback BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther. 2002;16(5):959–967.
   PubMed Web of Science ®Google Scholar
• Tack J, Van den Houte K, Carbone F. The unfulfilled promise of prokinetics for functional dyspepsia/postprandial distress syndrome. Am J Gastroenterol. 2019 Feb;114(2):204–206.
   PubMed Web of Science ®Google Scholar
• Bang CS, Kim JH, Baik GH, et al. Mosapride treatment for functional dyspepsia: a meta-analysis. J Gastroenterol Hepatol. 2015 Jan;30(1):28–42.
   Web of Science ®Google Scholar
• Du Y, Su T, Song X, et al. Efficacy and safety of cinitapride in the treatment of mild to moderate postprandial distress syndrome-predominant functional dyspepsia. J Clin Gastroenterol. 2014 Apr;48(4):328–335.
   PubMed Web of Science ®Google Scholar
• Robert M, Salvà M, Segarra R, et al. The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. Drug Metab Dispos. 2007 July;35(7):1149–1156.
   PubMed Web of Science ®Google Scholar
• Fernández AG, Massingham R. Peripheral receptor populations involved in the regulation of gastrointestinal motility and the pharmacological actions of metoclopramide-like drugs. Life Sci. 1985 Jan;36(1):1–14.
   PubMed Web of Science ®Google Scholar
• Holtmann G, Talley NJ, Liebregts T, et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006;354(8):832–840.
   PubMed Web of Science ®Google Scholar
• Carbone F, Vandenberghe A, Holvoet L, et al. 383 - The therapeutic outcome of itopride in functional dyspepsia postprandial distress syndrome: a double-blind randomized, multicenter, placebo-controlled study. Gastroenterology. 2018;154(6):S–91.
   Web of Science ®Google Scholar
• Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut. 2008;57(6):740–746.
   PubMed Web of Science ®Google Scholar
• Tack J. A phase II placebo controlled randomized trial with tegaserod (T) in functional dyspepsia (FD) patients with normal gastric emptying (NGE). Gastroenterology. 2002;122:154.
   Google Scholar
• Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol. 2008 Aug;103(8):1906–1919.
   PubMed Web of Science ®Google Scholar
• Ahn A, Barnes C, Shaywitz D, et al. Velusetrag improves gastric emptying time in subjects with diabetic or idiopathic gastroparesis. Gastroenterology. 2015;148(4): S–507. (abstract).
   Web of Science ®Google Scholar
• Abell T, Kuo B, Esfandyari T, et al. Velusetrag improves gastroparesis both in symptoms and gastric emptying in patients with diabetic or idiopathic gastroparesis in a 12-week global phase 2B study. Gastroenterology. 2019;156(6): S164. (abstract).
   Web of Science ®Google Scholar
• Carbone F, Van den Houte K, Clevers E, et al. Prucalopride in gastroparesis: a randomized placebo-controlled crossover study. Am J Gastroenterol. in press, 2019;114:1265–1274.
   Web of Science ®Google Scholar
• Dukes GE, Scimia C, Kuo B, et al. Safety, tolerability, and pharmacodynamics of TAK-906, A dopamine 2,3 antagonist, in patients with diabetic or idiopathic gastroparesis. Neurogastroenterol Motil. 2019;31(S3), 6 (abstract).
   Web of Science ®Google Scholar
• Pasricha PJ, Yates KP, Sarosiek I, et al. Aprepitant has mixed effects on nausea and reduces other symptoms in patients with gastroparesis and related disorders. Gastroenterology. 2018;154(1):65–76 e11.
   PubMed Web of Science ®Google Scholar
• Jacob D, Busciglio I, Burton D, et al. Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant. Am J Physiol Gastrointest Liver Physiol. 2017 Nov 1;313(5):G505–G510.
   PubMed Web of Science ®Google Scholar
• Van Oudenhove L, Kindt S, Vos R, et al. Influence of buspirone on gastric sensorimotor function in man. Aliment Pharmacol Ther. 2008 Dec 1;28(11–12):1326–1333.
   PubMed Web of Science ®Google Scholar
• Tack J, Janssen P, Masaoka T, et al. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol. 2012 Nov;10(11):1239–1245.
   PubMed Web of Science ®Google Scholar
• Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol. 2009 Nov;104(11):2779–2787.
   PubMed Web of Science ®Google Scholar
• Tack J, Van Den Elzen B, Tytgat G, et al. A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia. Neurogastroenterol Motil. 2009 June;21(6):619–626.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Matsuzaki J, Fukushima Y, et al. Rikkunshito study group. Randomized clinical trial: rikkunshito in the treatment of functional dyspepsia–a multicenter, double-blind, randomized, placebo-controlled study. Neurogastroenterol Motil. 2014 July;26(7):950–961.
   PubMed Web of Science ®Google Scholar
• Tominaga K, Sakata Y, Kusunoki H, et al. Rikkunshito simultaneously improves dyspepsia correlated with anxiety in patients with functional dyspepsia: a randomized clinical trial (the DREAM study). Neurogastroenterol Motil. 2018 July;30(7):e13319.
   PubMed Web of Science ®Google Scholar
• Papathanasopoulos A, Rotondo A, Janssen P, et al. Effect of acute peppermint oil administration on gastric sensorimotor function and nutrient tolerance in health. Neurogastroenterol Motil. 2013;25(4):e263–271.
   PubMed Web of Science ®Google Scholar
• Micklefield G, Jung O, Greving I, et al. Effects of intraduodenal application of peppermint oil (WS(R) 1340) and caraway oil (WS(R) 1520) on gastroduodenal motility in healthy volunteers. Phytother Res. 2003;17(2):135–140.
   PubMed Web of Science ®Google Scholar
• May B, Kohler S, Schneider B. Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther. 2000;14(12):1671–1677.
   PubMed Web of Science ®Google Scholar
• Rich G 1,2, Shah A 1,2, Koloski N 1,2,3, et al. A randomized placebo-controlled trial on the effects of Menthacarin, a proprietary peppermint- and caraway-oil-preparation, on symptoms and quality of life in patients with functional dyspepsia. Neurogastroenterol Motil. 2017 Nov;29(11):e13132.
   PubMed Web of Science ®Google Scholar
• Chey WD, Lacy BE, Cash BD, et al. Sa1619 - efficacy of caraway oil/L-menthol plus usual care vs placebo plus usual care, in functional dyspepsia patients with post-prandial distress (PDS) or epigastric pain (EPS) syndromes: results from a us RCT. Gastroenterology. 2017;152(5): S307. (abstract).
   PubMed Web of Science ®Google Scholar
• Ottilinger B, Storr M, Malfertheiner P, et al. STW5 - a safe and effective standard in the treatment for functional gastrointestinal disorders. Wien Med Wochenschr. 2013 Feb;163(3–4):65–72.
   PubMedGoogle Scholar
• Madisch A, Holtmann G, Mayr G, et al. Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebo-controlled, multicenter trial. Digestion. 2004;69:45–52.
   PubMed Web of Science ®Google Scholar
• von Arnim U, Peitz U, Vinson B, et al. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo‐controlled double-blind study. Am J Gastroenterol. 2007;102:1268–1275.
   PubMed Web of Science ®Google Scholar
• Madisch A, Vinson BR, Abdel-Aziz H, et al. Modulation of gastrointestinal motility beyond metoclopramide and domperidone: pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders. Wien Med Wochenschr. 2017 May;167(7–8):160–168.
   PubMedGoogle Scholar
• Gerhardt F, Benesic A, Tillmann HL, et al. Iberogast-induced acute liver failure-reexposure and in vitro assay support causality. Am J Gastroenterol. 2019 Aug;114(8):1358–1359.
   PubMed Web of Science ®Google Scholar
• Quigley EM, Lacy BE. Overlap of functional dyspepsia and GERD–diagnostic and treatment implications. Nat Rev Gastroenterol Hepatol. 2013 Mar;10(3):175–186.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology. 2004;127(5):1329–1337.
   PubMed Web of Science ®Google Scholar
• Asaoka D, Nagahara A, Hojo M, et al. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. Biomed Rep. 2017 Feb;6(2):175–180.
   PubMed Web of Science ®Google Scholar
• Tack J, Caenepeel P, Fischler B, et al. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology. 2001 Sept;121(3):526–535.
   PubMed Web of Science ®Google Scholar
• Van Oudenhove L, Vandenberghe J, Geeraerts B, et al. Relationship between anxiety and gastric sensorimotor function in functional dyspepsia. Psychosom Med. 2007 June;69(5):455–463.
   PubMed Web of Science ®Google Scholar
• Farré R, Vanheel H, Vanuytsel T, et al. In functional dyspepsia, hypersensitivity to postprandial distention correlates with meal-related symptom severity. Gastroenterology. 2013 Sept;145(3):566–573.
   PubMed Web of Science ®Google Scholar
• Talley NJ, Locke GR, Saito YA, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology. 2015;149(2):340–349.e342.
   PubMed Web of Science ®Google Scholar
• Lacy B, Saito Y, Camilleri M, et al. Effects of antidepressants on gastric function in patients with functional dyspepsia. Am J Gastroenterol. 2018;113:216–224.
   PubMed Web of Science ®Google Scholar
• Tack J, Broekaert D, Coulie B, et al. Influence of the selective serotonin reuptake inhibitor paroxetine on gastric sensorimotor function in man. Aliment Pharmacol Ther. 2003 Feb 15;17(4):603–608.
   PubMed Web of Science ®Google Scholar
• Chial HJ, Camilleri M, Burton D, et al. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol. 2003 Jan;284(1):G130–7.
   PubMed Web of Science ®Google Scholar
• Tack J, Ly HG, Carbone F, et al. Efficacy of mirtazapine in patients with functional dyspepsia and weight loss. Clin Gastroenterol Hepatol. 2016;14(3):385–392.e384.
   PubMed Web of Science ®Google Scholar
• Carbone F, Vanuytsel T, Tack J. The effect of mirtazapine on gastric accommodation, gastric sensitivity to distention, and nutrient tolerance in healthy subjects. Neurogastroenterol Motil. 2017;29(12):e13146.
   Web of Science ®Google Scholar
• Corsetti M, Tack J. Linaclotide: a new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation. United European Gastroenterol J. 2013 Feb;1(1):7–20.
   PubMed Web of Science ®Google Scholar
• Kessler M, Solinga R, Zimmer D, et al. IW-9179, a phosphopeptide designed to target the upper gastrointestinal tract, is more potent at acidic pH and is rapidly metabolized in vitro in rodent intestinal fluid. Gastroenterology. 2015;148(4 Supplement 1): S–823. (abstract).
   Web of Science ®Google Scholar
• Tack J, Fitch D, Shao J, et al. Evaluation of daily GI symptoms in a Phase 2a study of IW-9179 in functional dyspepsia (abstract #P1637). Am J Gastroenterol. 2014;109:S637–S638.
   PubMed Web of Science ®Google Scholar
• Ironwood pharmaceuticals reports top-line data from exploratory Phase IIa study of IW-9179 in diabetic gastroparesis. (Ironwood press release); 2016 Apr.
   Google Scholar
• Ameloot K, Janssen P, Scarpellini E, et al. Endocannabinoid control of gastric sensorimotor function in man. Aliment Pharmacol Ther. 2010 May;31(10):1123–1131.
   PubMed Web of Science ®Google Scholar
• Ly HG, Ceccarini J, Weltens N, et al. Increased cerebral cannabinoid-1 receptor availability is a stable feature of functional dyspepsia: a [F]MK-9470 PET study. Psychother Psychosom. 2015;84(3):149–158.
   PubMed Web of Science ®Google Scholar
• Higgins P, Ginsburg D, Gilder K, et al. P418 Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn’s disease. Ecco. 2019;P418.
   Google Scholar
• Sugano K, Tack J, Kuipers EJ, et al., faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on helicobacter pylori gastritis. Gut. 2015;64:1353–1367.
   PubMed Web of Science ®Google Scholar
• Zhong L, Shanahan ER, Raj A, et al. Dyspepsia and the microbiome: time to focus on the small intestine. Gut. 2017 June;66(6):1168–1169.
   PubMed Web of Science ®Google Scholar
• Igarashi M, Nakae H, Matsuoka T, et al. Alteration in the gastric microbiota and its restoration by probiotics in patients with functional dyspepsia. BMJ Open Gastro. 2017;3:e000144.
   Google Scholar
• Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016 Dec;151(6):1113–1121.
   PubMed Web of Science ®Google Scholar
• Kimer N, Krag A, Møller S, et al. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther. 2014 July;40(2):123–132.
   PubMed Web of Science ®Google Scholar
• Tan VP, Liu KS, Lam FY, et al. Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia. Aliment Pharmacol Ther. 2017 Mar;45(6):767–776.
   PubMed Web of Science ®Google Scholar
• Wauters L, Walker MM, Tack J, et al. Duodenal implications in the pathophysiology and treatment of functional dyspepsia. Submitted for publication; 2019.
   Google Scholar
• Potter MDE, Goodsall TM, Walker MM, et al. Dual histamine blockade for the treatment of adult functional dyspepsia: a single centre experience. Gut. 2019 Apr 30. pii: gutjnl-2019-318412. doi: 10.1136/gutjnl-2019-318412. [Epub ahead of print]
   Google Scholar
• Friesen CA, Sandridge L, Andre L, et al. Mucosal eosinophilia and response to H1/H2 antagonist and cromolyn therapy in pediatric dyspepsia. Clin Pediatr (Phila). 2006;45:143–147.
   PubMed Web of Science ®Google Scholar
• Friesen CA, Kearns GL, Andre L, et al. Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr. 2004;38:343–351.
   PubMed Web of Science ®Google Scholar
• Potter MDE, Wood NK, Walker MM, et al. Proton pump inhibitors and suppression of duodenal eosinophilia in functional dyspepsia. Gut. 2018;gutjnl-2018-316878. DOI:10.1136/gutjnl-2018-316878
   Web of Science ®Google Scholar
• Wauters L, Ceulemans M, Lambaerts M, et al. Duodenal hyperpermeability, eosinophilia and symptoms in functional dyspepsia patients are reduced by proton pump inhibitors. Neurogastroenterol Motil. 2019;31(S4):22–23.
   Google Scholar
• Van den Houte K, Carbone F, Goelen N, et al. The impact of the Rome IV definitions on functional dyspepsia subgroups in secondary care. Submitted for publication; 2019.
   Google Scholar
• Carbone F, Vanuytsel T, Tack J. Analysis of postprandial symptom patterns in subgroups of patients with Rome III or Rome IV functional dyspepsia. Clin Gastroenterol Hepatol. 2019 Aug 5. pii: S1542-3565(19)30842-0. doi: 10.1016/j.cgh.2019.07.053. [Epub ahead of print]
   Google Scholar